Business
Sernova to Participate in Multiple U.S. Healthcare Investor Conferences
(TheNewswire) Sernova Engages Leading U.S.-Based Healthcare Communications Fi...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova to Participate in Multiple U.S. Healthcare Investor Conferences\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Sernova Engages Leading U.S.-Based Healthcare\nCommunications Firm to Broaden Awareness of Potential ‘Functional\nCure’ Technology for Type 1 Diabetes\n \n \n \n \n LONDON, ONTARIO –\n \n \n TheNewswire -\n \n \n May 5, 2022 – Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH), a clinical stage regenerative medicine\ncompany focused on developing a potential ‘functional cure’ for\ntype 1 diabetes (T1D) and other chronic diseases including hemophilia\nA and thyroid disease, today announced that the company will be\nparticipating in several upcoming U.S. healthcare industry and\ninvestor conferences. Conference details are provided below.\n \n \n \n \n The Company is also pleased to announce it has engaged\nNew York-based LifeSci Communications, a global life science and\nmedical technologies-focused communications and marketing agency.\nLifeSci Communications will assist Sernova to expand and elevate its\nprofile through strategic communications and public relations. Sernova\nis also working with affiliate LifeSci Advisors LLC, a leading\ninvestor relations consultancy firm serving life science companies,\nproviding institutional investor communications and capital markets\noutreach services in support of the Company’s U.S. capital markets\nobjectives.\n \n \n \n \n “With multiple collaborations advancing across our\npipeline and growing interest in our best-in-class cell therapy\ntherapeutic solution platform - consisting of immune protected\ntherapeutic cells and our proprietary Cell Pouch\n \n \n ™ medical device -\n \n \n as a potential\n‘functional cure’ for multiple patient populations, the timing is\nright to drive awareness of our unique cell therapy proposition and\nunprecedented clinical results including the demonstration of\ncontinuous insulin independence for over two years now in our most\nadvanced Phase 1/2 T1D study patient, in contrast to the clinical\nsetbacks of several of our peer companies,” commented Dr. Philip\nToleikis, President & CEO of Sernova.\n \n \n \n \n UPCOMING U.S. HEALTHCARE INDUSTRY AND\nINSTITUTIONAL INVESTOR PRESENTATIONS\n \n \n \n \n Event\n \n \n :      \n   ...